An analysis of patient-reported outcomes showed that osimertinib yielded a longer time to deterioration compared with chemotherapy in patients with advanced non–small-cell lung cancer.
A UK team found multiple targets of non-coding mutations, highlighting the importance of broadening the search for cancer drivers into the regulatory genome.
Routinely available patient and tumor features accurately predicted the risk progression and death from RCC post nephrectomy, a Mayo Clinic team found.
The FDA granted approval to the combination of dabrafenib and trametinib for the adjuvant treatment of melanoma, specifically in patients with a BRAF V600E or V600K mutation.
A laboratory study has found that the HER2 inhibitor lapatinib used to slow HER2-positive breast cancer can actually induce tumor growth in some circumstances.
The approval includes adults with R/R DLBCL after two or more lines of prior systemic therapy, high-grade B-cell lymphoma, and DLBCL arising from FL.
Challenge yourself with our latest quiz, covering management considerations in the treatment of patients with transplant-ineligible myeloma.
Investigators concluded further investigations are warranted in elderly patients with either stable or responsive disease after bortezomib induction therapy.
A pooled retrospective analysis of nearly 5,000 mRCC patients in phase II and III trials showed PFS among NSAIDs users was half that of NSAIDs nonusers.
Activating CD40 is “a key to initiating a T-cell response to tumors,” says Dr. Robert Vonderheide, MD, director of U Penn’s Abramson Cancer Center.
A retrospective study of ICIs by French investigators found manageable toxicity in patients over age 70, and survival outcomes comparable to younger patients.
An at-home online survey was found to be a reasonably accurate way to collect patient comorbidities prior to a physician visit in patients with prostate cancer.
T-ALL may be treatable by targeting signaling pathways affected by STIL-TAL1 fusion, according to a team from The Institute of Cancer Research, London, UK.
The significantly better PFS compared with sunitinib supports cabozantinib as initial therapy for patients with advanced RCC of intermediate or poor risk.
In this podcast, Dr. Emmanuel Antonarakis discusses his novel clinical trial evaluating PARP inhibitors in high-risk and biochemically recurrent prostate cancer.